406 related articles for article (PubMed ID: 32960984)
1. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review.
Bierhoff M; Smolders EJ; Tarning J; Burger DM; Spijker R; Rijken MJ; Angkurawaranon C; McGready R; White NJ; Nosten F; van Vugt M
Antivir Ther; 2019; 24(7):529-540. PubMed ID: 31868655
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of tenofovir during pregnancy and postpartum.
Best BM; Burchett S; Li H; Stek A; Hu C; Wang J; Hawkins E; Byroads M; Watts DH; Smith E; Fletcher CV; Capparelli EV; Mirochnick M;
HIV Med; 2015 Sep; 16(8):502-11. PubMed ID: 25959631
[TBL] [Abstract][Full Text] [Related]
5. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
[TBL] [Abstract][Full Text] [Related]
6. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection.
Celen MK; Mert D; Ay M; Dal T; Kaya S; Yildirim N; Gulsun S; Barcin T; Kalkanli S; Dal MS; Ayaz C
World J Gastroenterol; 2013 Dec; 19(48):9377-82. PubMed ID: 24409065
[TBL] [Abstract][Full Text] [Related]
8. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
[TBL] [Abstract][Full Text] [Related]
9. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of hepatitis B surface antigen in pregnant women with and without tenofovir disoproxil fumarate.
Chang HL; Wen WH; Lee CN; Chiu YE; Liu CJ; Chang MH; Lin LH; Chen HL
J Viral Hepat; 2022 Feb; 29(2):107-114. PubMed ID: 34724288
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes.
Chen HL; Lee CN; Chang CH; Lai MW; Tsai MC; Mu SC; Liu CJ; Shih JC; Wen WH; Hu RT; Huang CP; Hu KC; Chen CP; Lee CL; Chien RN; Chang KC; Hsu HY; Lee CC; Ni YH; Chang MH
Liver Int; 2024 Jun; 44(6):1422-1434. PubMed ID: 38456620
[TBL] [Abstract][Full Text] [Related]
12. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Van Rompay KK; Durand-Gasselin L; Brignolo LL; Ray AS; Abel K; Cihlar T; Spinner A; Jerome C; Moore J; Kearney BP; Marthas ML; Reiser H; Bischofberger N
Antimicrob Agents Chemother; 2008 Sep; 52(9):3144-60. PubMed ID: 18573931
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.
Cressey TR; Harrison L; Achalapong J; Kanjanavikai P; Patamasingh Na Ayudhaya O; Liampongsabuddhi P; Siriwachirachai T; Putiyanun C; Suriyachai P; Tierney C; Salvadori N; Chinwong D; Decker L; Tawon Y; Murphy TV; Ngo-Giang-Huong N; Siberry GK; Jourdain G;
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275094
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.
Benaboud S; Hirt D; Launay O; Pannier E; Firtion G; Rey E; Bouazza N; Foissac F; Chappuy H; Urien S; Tréluyer JM
Antimicrob Agents Chemother; 2012 Feb; 56(2):857-62. PubMed ID: 22123690
[TBL] [Abstract][Full Text] [Related]
16. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Kayes T; Crane H; Symonds A; Dumond J; Cottrell M; Di Girolamo J; Manandhar S; Lim TH; Gane E; Kashuba A; Levy MT
Aliment Pharmacol Ther; 2022 Aug; 56(3):510-518. PubMed ID: 35599363
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
[TBL] [Abstract][Full Text] [Related]
18. Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate.
Li S; Jin J; Jiang Y; Shi J; Jiang X; Lin N; Ma Z
Int J Antimicrob Agents; 2023 Mar; 61(3):106726. PubMed ID: 36646229
[TBL] [Abstract][Full Text] [Related]
19. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.
Eke AC; Shoji K; Best BM; Momper JD; Stek AM; Cressey TR; Mirochnick M; Capparelli EV
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
